Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NKTX Nkarta > Detailed Quotes

NKTX Nkarta

Watchlist
5.730
-0.070-1.21%
Trading Session  02/03 09:44 ET
High
5.805
Open
5.720
Turnover
206.73K
Low
5.620
Pre Close
5.800
Volume
36.26K
Market Cap
279.70M
P/E(TTM)
Loss
52wk High
20.350
Shares
48.81M
P/E(Static)
Loss
52wk Low
4.830
Float Cap
178.60M
Bid/Ask %
-20.00%
Historical High
79.160
Shs Float
31.17M
Volume Ratio
1.83
Historical Low
4.830
Dividend TTM
--
Div Yield TTM
--
P/B
0.70
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.12%
Amplitude
3.19%
Avg Price
5.701
Lot Size
1
Float Cap
178.60M
Bid/Ask %
-20.00%
Historical High
79.160
Shs Float
31.17M
Volume Ratio
1.83
Historical Low
4.830
Dividend TTM
--
P/B
0.70
Dividend LFY
--
Turnover Ratio
0.12%
Amplitude
3.19%
Avg Price
5.701
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
CEO: Mr. Paul J. Hastings
Market: NASDAQ
Listing Date: 07/10/2020
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist